Efficacy of neratinib (HK1-272) in the treatment of patients with ErbB2 + metastatic breast cancer

Back ground: The monoclonal antibody trastuzumab has improved theoutcomes of patients with breast cancer that over expresses the the humanepidermal grouth factor receptor 2 (HER2).However despite thisadventage,many tumors develop resistance and novel approaches areneeded.Recently,a greater understanding of cellular biology has translated intothe development of novel anti HER2 agents with varying mechanisms ofaction.Neratinib ,a pan HER2 tyrosin kinase inhibitor,with irreversibly inhibitHER1,and HER2,also has proven activity in metastatic breast cancer.Methodes:Computerized searches was performed to identify published clinicaltrials about use of Neratinib (HK1-272) in treatment for HER2+ breast cancerbetween December 2009 and oct.2012.Three phase 2 trials were include .Inthese trials ORRin patients who had trastuzumab previosely ,24-26% and fortrastuzumab.naive patients 56% and PSF=22.3 wks and 39.6 wks respectively.Conclusion:Oral neratinit shoued substantial clinical activity and wasreasonably well tolerated among both heavily pretreated and trastuzumb-naviepatients who had advanced ErbB2 positive breast cancer .

کلیدواژه ها:

Trastuzumb ، HER2 ، Neratinib ، Pan HER2 tyrosin kinase inhibitor ، HER1